Glycorex Transplantation AB Signs Distribution Agreement for Brazil
Glycorex Transplantation AB has entered into a distribution agreement with Grupo VIDA for its Glycosorb® ABO product in Brazil. This move is part of the company's strategy to expand its market reach.
Glycorex Transplantation AB has signed a distribution agreement with Grupo VIDA, granting the Brazilian company rights to distribute Glycosorb® ABO in Brazil. This agreement marks another step in Glycorex's ongoing strategy to broaden its international market presence.
Grupo VIDA is a well-established medical technology distributor with 23 years of experience serving the Brazilian healthcare market. The company has a proven track record with blood banks and bone marrow transplant centers and is now expanding its operations to include organ transplant services.
Glycosorb® ABO is designed to prevent organ rejection in ABO-incompatible transplants, potentially increasing the number of patients who can receive life-saving organ transplants. The technology aims to overcome a significant barrier in transplantation medicine.
The company views this partnership as a key opportunity to access one of the largest healthcare markets globally. Glycorex anticipates that the agreement will strengthen its position as a provider of transplant technologies worldwide.